Biogen Inc Aktie und aktueller Aktienkurs: Bleiben Sie über den aktuellen Aktienkurs von Biogen Inc (BIIB) stets informiert - direkt auf dieser Seite. Behalten Sie den vor- und nachbörslichen ...

Im Wahlkreis Schwarzwald-Baar ist die Linke traditionell eher schwach. Der non-binären Person Heinrich Alexandra Hermann gelingt der Clou: Die non-binäre Person sichert der Partei 5,7 Prozent ...

Deep-pocketed investors have adopted a bullish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

In a video shared on X, IIT Baba confidently claimed, "Main tumko pehle se bol raha hu, is baar India nahi jeetegi" (I am telling you in advance, this time India will not win). He further challenged ...

Zorevunersen is intended for treating Dravet syndrome. Credit: Maks_lab/Shutterstock. Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat ...

Schwarzwald-Baar-Kreis Wetter heute: So frostig wird es am Dienstag: Schwarzwald-Baar-Kreis-Wetter mit Wetterwarnung vor Frost: Wie wird das Wetter heute im Schwarzwald-Baar-Kreis? Die ...

CAMBRIDGE, Mass. & BEDFORD, Mass.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the ...

Through a new deal, Biogen has bought access to a potentially first-of-its-kind drug that some doctors and analysts see as a promising treatment for a rare form of epilepsy. Biogen on Tuesday ...

Through a new deal, Biogen has bought access to a potentially first-of-its-kind drug that some doctors and analysts see as a promising treatment for a rare form of epilepsy. Biogen on Tuesday agreed ...

Biogen’s leadership has said they aren’t eager to deal, but turns out Stoke Therapeutics had a little something in its rare disease catalog that prompted Biogen to strike. The companies will work on a ...

Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing ...